Literature DB >> 27214080

All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.

P Kruger1, J Cooney1, I Nivison-Smith2, A Dodds3, P Bardy4, D Ma3, J Szer5, S Durrant6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27214080     DOI： 10.1038/bmt.2016.143

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

Authors:  Erica Warlick; Kwang Woo Ahn; Tanya L Pedersen; Andrew Artz; Marcos de Lima; Michael Pulsipher; Gorgun Akpek; Mahmoud Aljurf; Jean-Yves Cahn; Mitchell Cairo; Yi-Bin Chen; Brenda Cooper; Abhinav Deol; Sergio Giralt; Vikas Gupta; H Jean Khoury; Holbrook Kohrt; Hillard M Lazarus; Ian Lewis; Richard Olsson; Joseph Pidala; Bipin N Savani; Matthew Seftel; Gerard Socié; Martin Tallman; Celaettin Ustun; Ravi Vij; Lars Vindeløv; Daniel Weisdorf
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

2.  A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.

Authors:  Martin Weisser; Johanna Tischer; Susanne Schnittger; Claudia Schoch; Georg Ledderose; Hans Jochem Kolb
Journal:  Haematologica       Date:  2006-04-19       Impact factor: 9.941

3.  Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004.

Authors:  Ian Nivison-Smith; Kenneth F Bradstock; Anthony J Dodds; Patricia A Hawkins; David D F Ma; John J Moore; Judy M Simpson; Jeff Szer
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-23       Impact factor: 5.742

4.  Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.

Authors:  H Jiang; L-P Xu; D-H Liu; K-Y Liu; S-S Chen; B Jiang; Q Jiang; H Chen; Y-H Chen; W Han; X-H Zhang; Y Wang; J-Z Wang; F-R Wang; Y-Z Qin; Y-Y Lai; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-07-21       Impact factor: 5.483

Review 5.  The EBMT risk score.

Authors:  A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2011-06-06       Impact factor: 5.483

6.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

7.  Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.

Authors:  Elias Jabbour; Jorge Cortes; Fabio P S Santos; Dan Jones; Susan O'Brien; Gabriela Rondon; Uday Popat; Sergio Giralt; Partow Kebriaei; Roy B Jones; Hagop Kantarjian; Richard Champlin; Marcos de Lima
Journal:  Blood       Date:  2010-12-14       Impact factor: 22.113

8.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.

Authors:  Stephanie J Lee; Manisha Kukreja; Tao Wang; Sergio A Giralt; Jeffrey Szer; Mukta Arora; Ann E Woolfrey; Francisco Cervantes; Richard E Champlin; Robert Peter Gale; Joerg Halter; Armand Keating; David I Marks; Philip L McCarthy; Eduardo Olavarria; Edward A Stadtmauer; Manuel Abecasis; Vikas Gupta; H Jean Khoury; Biju George; Gregory A Hale; Jane L Liesveld; David A Rizzieri; Joseph H Antin; Brian J Bolwell; Matthew H Carabasi; Edward Copelan; Osman Ilhan; Mark R Litzow; Harold C Schouten; Axel R Zander; Mary M Horowitz; Richard T Maziarz
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

Review 9.  Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

Authors:  Richard Champlin; Marcos de Lima; Partow Kebriaei; Gabriela Rondon; Tobi Fisher; Elias Jabbour; Jorge E Cortés; Hagop Kantarjian; Paolo Anderlini; Amin Alousi; Chitra Hosing; Elizabeth Shpall; Uday Popat; Muzaffar Qazilbash; Borje Andersson; Sergio Giralt
Journal:  Clin Lymphoma Myeloma       Date:  2009

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more
  1 in total

1.  Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.

Authors:  Preetesh Jain; Hagop M Kantarjian; Ahmad Ghorab; Koji Sasaki; Elias J Jabbour; Graciela Nogueras Gonzalez; Rashmi Kanagal-Shamanna; Ghayas C Issa; Guillermo Garcia-Manero; Devendra Kc; Sara Dellasala; Sherry Pierce; Marina Konopleva; William G Wierda; Srdan Verstovsek; Naval G Daver; Tapan M Kadia; Gautam Borthakur; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Jorge E Cortes
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.